Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
$2.40
+0.8%
$2.06
$1.55
$5.59
$16.71M0.3934,630 shs6,882 shs
Gelteq Limited stock logo
GELS
Gelteq
$1.87
+2.2%
$1.83
$0.77
$5.50
$17.27MN/A193,178 shs80,271 shs
Passage Bio, Inc. stock logo
PASG
Passage Bio
$5.73
-0.9%
$7.53
$5.12
$26.60
$18.03M1.6769,939 shs166,187 shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$1.02
+4.9%
$0.73
$0.36
$737.44
$3.56M0.725.01 million shs14.72 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-2.06%+5.31%+19.00%+1.28%-51.03%
Gelteq Limited stock logo
GELS
Gelteq
-6.15%+7.65%+16.56%-21.12%+182,999,900.00%
Passage Bio, Inc. stock logo
PASG
Passage Bio
+1.94%+3.96%-13.68%-11.08%-65.22%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-2.74%+8.07%+143.15%-16.87%-99.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
1.5049 of 5 stars
2.05.00.00.00.61.70.6
Gelteq Limited stock logo
GELS
Gelteq
N/AN/AN/AN/AN/AN/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
2.5637 of 5 stars
3.52.00.00.00.62.51.3
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
2.9728 of 5 stars
3.05.00.00.02.90.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
4.00
Strong Buy$5.00108.33% Upside
Gelteq Limited stock logo
GELS
Gelteq
0.00
N/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
3.00
Buy$150.002,517.80% Upside
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
2.00
Hold$350.0034,213.73% Upside

Current Analyst Ratings Breakdown

Latest WINT, PASG, GELS, and EDSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$5.00
6/24/2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00
(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/A$0.61 per shareN/A
Gelteq Limited stock logo
GELS
Gelteq
$100K176.53N/AN/A$1.30 per share1.44
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/A$19.84 per shareN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/A$38.99 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)
Gelteq Limited stock logo
GELS
Gelteq
-$2.33MN/A0.00N/AN/AN/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$64.77M-$20.40N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$1.79M-$823.47N/AN/AN/AN/A-227.93%-56.46%8/18/2025 (Estimated)

Latest WINT, PASG, GELS, and EDSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$0.20N/AN/AN/AN/AN/A
8/8/2025N/A
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.23N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A
5/14/2025Q2 2025
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
-$0.30-$0.30N/A-$0.30N/AN/A
5/13/2025Q1 2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$4.80-$5.00-$0.20-$0.25N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/AN/AN/AN/AN/A
Gelteq Limited stock logo
GELS
Gelteq
N/AN/AN/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
N/A
15.72
15.72
Gelteq Limited stock logo
GELS
Gelteq
N/A
0.79
N/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/A
3.74
3.74
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/A
0.25
0.25

Institutional Ownership

CompanyInstitutional Ownership
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
5.50%
Gelteq Limited stock logo
GELS
Gelteq
N/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
53.48%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
29.33%

Insider Ownership

CompanyInsider Ownership
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
22.60%
Gelteq Limited stock logo
GELS
Gelteq
N/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
5.00%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Edesa Biotech, Inc. stock logo
EDSA
Edesa Biotech
207.02 million5.44 millionNot Optionable
Gelteq Limited stock logo
GELS
Gelteq
N/A9.44 millionN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
1303.12 million2.96 millionOptionable
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
303.66 million3.65 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Edesa Biotech stock logo

Edesa Biotech NASDAQ:EDSA

$2.40 +0.02 (+0.84%)
Closing price 03:53 PM Eastern
Extended Trading
$2.58 +0.18 (+7.50%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Gelteq stock logo

Gelteq NASDAQ:GELS

$1.87 +0.04 (+2.19%)
As of 04:00 PM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Passage Bio stock logo

Passage Bio NASDAQ:PASG

$5.73 -0.05 (-0.87%)
Closing price 04:00 PM Eastern
Extended Trading
$6.26 +0.52 (+9.16%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Windtree Therapeutics stock logo

Windtree Therapeutics NASDAQ:WINT

$1.02 +0.05 (+4.87%)
Closing price 04:00 PM Eastern
Extended Trading
$1.01 -0.01 (-0.98%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.